Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.

التفاصيل البيبلوغرافية
العنوان:	Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
المؤلفون:	Behr, Jürgen, Demedts, Maurits, Buhl, Roland, Costabel, Ulrich, Dekhuijzen, Richard P N, Jansen, Henk M, MacNee, William, Thomeer, Michiel, Wallaert, Benoit, Laurent, Francois, Nicholson, Andrew G, Verbeken, Eric K, Verschakelen, Johny, Flower, C D R, Petruzzelli, Stefano, De Vuyst, Paul, van den Bosch, J M M, Rodriguez-Becerra, Eulogio, Lankhorst, Ida, Sardina, Marco, Boissard, Gabrielle
المساهمون:	The Ifigenia study group, Behr,J Medizinische Klinik I, Klinikum Grosshadern der Ludwig Maximilians-Universität, München, Germany. Demedts,M, Thomeer,M, Verbeken,EK, Verschakelen,J University Hospital, Katholieke Universiteit Leuven, Belgium. Buhl,R III Medizinische Klinik, Klinikum der Johannes Gutenberg-Universität, Mainz, Germany. Costabel,U Medical Faculty University of Duisburg-Essen and Ruhrlandklinik, Essen-Heidhausen, Germany. Dekhuijzen,RPN University Medical Centre Nijmegen, the Netherlands. Jansen,HM Academic Medical Centre, Amsterdam, the Netherlands. MacNee,W University of Edinburgh Medical School, Edinburgh, UK. Wallaert,B CHRU de Lille, Hôpital Calmette, Lille, France. Laurent,F Hâopital Cardiologique, CHU de Bordeaux, France. Nicholson,AG Royal Brompton Hospital, UK. Flower,CDR Evelyn Hospital, Cambridge, UK. Petruzzelli,S Dipartimento Cardio-Toracico, Università degli Studi di Pisa, Italy. De Vuyst,P Université Libre de Bruxelles, Erasmus Hospital, Brussels, Belgium. Van den Bosch,JMM St Antonius Ziekenhuis Nieuwegein, the Netherlands. Rodriguez-Becerra,E Hospital Universitario Virgen del Rocio, Sevilla, Spain. Lankhorst,I, Sardina,M, Boissard,G Zambon Group, Bresso, Milan, Italy.
بيانات النشر:	BIOMED CENTRAL LTD
سنة النشر:	2009
المجموعة:	Sistema Sanitario Público de Andalucía (SSPA): Repositorio
مصطلحات موضوعية:	Anciano, Azatioprina, Progresión de la efermedad, Método doble ciego, Quimioterapia combinada, Europa (continente), Prueba de esfuerzo, Femenino, Humanos, Pulmón, Fibrosis pulmonar Idiopática, Mediana edad, Pacientes desistentes del Tratamiento, Prednisona, Fármacos del sistema respiratorio, Índice de severidad de la enfermedad, Resultado del tratamiento, Capacidad vital, Acetilcisteína, Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Aged, Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thionucleosides::Azathioprine, Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression, Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Double-Blind Method, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination, Medical Subject Headings::Geographicals::Geographic Locations::Europe, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Cardiovascular::Heart Function Tests::Exercise Test
الوصف:	Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't;Trial Registration: Registered at http://www.ClinicalTrials.gov; number NCT00639496. ; BACKGROUND The randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine, significantly ameliorates (i.e. slows down) disease progression in terms of vital capacity (VC) (+9%) and diffusing capacity (DLco) (+24%) in idiopathic pulmonary fibrosis (IPF). To better understand the clinical implications of these findings we performed additional, explorative analyses of the IFGENIA data set. METHODS We analysed effects of NAC on VC, DLco, a composite physiologic index (CPI), and mortality in the 155 study-patients. RESULTS In trial completers the functional indices did not change significantly with NAC, whereas most indices deteriorated with placebo; in non-completers the majority of indices worsened but decline was generally less pronounced in most indices with NAC than with placebo. Most categorical analyses of VC, DLco and CPI also showed favourable changes with NAC. The effects of NAC on VC, DLco and CPI were significantly better if the baseline CPI was 50 points or lower. CONCLUSION This descriptive analysis confirms and extends the favourable effects of NAC on lung function in IPF and emphasizes the usefulness of VC, DLco, and the CPI for the evaluation of a therapeutic effect. Most importantly, less progressed disease as indicated by a CPI of 50 points or lower at baseline was more responsive to therapy in this study. ; Yes
نوع الوثيقة:	article in journal/newspaper
وصف الملف:	application/pdf
اللغة:	English
تدمد:	1465-9921 1465-993X
Relation:	http://respiratory-research.com/content/10/1/101/abstract; Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, et al. Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir. Res. 2009; 10:101; http://hdl.handle.net/10668/1657; PMC2774307
DOI:	10.1186/1465-9921-10-101
الاتاحة:	http://hdl.handle.net/10668/1657 https://doi.org/10.1186/1465-9921-10-101
Rights:	open access
رقم الانضمام:	edsbas.8B5DCAF6
قاعدة البيانات:	BASE

View record in BASE

Full Text Finder

الوصف
تدمد:	14659921 1465993X
DOI:	10.1186/1465-9921-10-101